[go: up one dir, main page]

MX2019012566A - Vnar con actividad anti-angiogenica en tumores solidos de animales de compa?ia. - Google Patents

Vnar con actividad anti-angiogenica en tumores solidos de animales de compa?ia.

Info

Publication number
MX2019012566A
MX2019012566A MX2019012566A MX2019012566A MX2019012566A MX 2019012566 A MX2019012566 A MX 2019012566A MX 2019012566 A MX2019012566 A MX 2019012566A MX 2019012566 A MX2019012566 A MX 2019012566A MX 2019012566 A MX2019012566 A MX 2019012566A
Authority
MX
Mexico
Prior art keywords
vnar
solid tumours
angiogenic activity
pet animals
genera
Prior art date
Application number
MX2019012566A
Other languages
English (en)
Inventor
Elosua Portugal Carolina
Fedorovish Licea Navarro Alexei
Vanessa Millán Gómez Dalia
Noemi Sánchez Campos Liliana
Fernando Paniagua Solís Jorge
DUEÑAS ESPINOZA Salvador
Original Assignee
Centro De Investig Cientifica Y De Educacion Superior De Ensenada Baja California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Investig Cientifica Y De Educacion Superior De Ensenada Baja California filed Critical Centro De Investig Cientifica Y De Educacion Superior De Ensenada Baja California
Publication of MX2019012566A publication Critical patent/MX2019012566A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

La presente invención se refiere a una novedosa proteína vNAR de SEQ ID No:1 capaz de inhibir la actividad del VEGF en mamíferos carnívoros de los géneros Canis y Felis, inhibiendo por consiguiente los tumores sólidos de ambos géneros.
MX2019012566A 2017-04-21 2018-04-20 Vnar con actividad anti-angiogenica en tumores solidos de animales de compa?ia. MX2019012566A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762488634P 2017-04-21 2017-04-21
PCT/MX2018/050010 WO2018194441A1 (es) 2017-04-21 2018-04-20 Vnar con actividad anti-angiogénica en tumores sólidos de animales de compañía

Publications (1)

Publication Number Publication Date
MX2019012566A true MX2019012566A (es) 2019-12-02

Family

ID=63857090

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012566A MX2019012566A (es) 2017-04-21 2018-04-20 Vnar con actividad anti-angiogenica en tumores solidos de animales de compa?ia.

Country Status (3)

Country Link
US (1) US11155612B2 (es)
MX (1) MX2019012566A (es)
WO (1) WO2018194441A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002319544B2 (en) 2001-08-10 2008-07-10 Aberdeen University Antigen binding domains from fish
EP1751181B1 (en) 2004-06-02 2012-08-15 AdAlta Pty Ltd BINDING MOIETIES BASED ON SHARK IgNAR DOMAINS
WO2011056056A2 (es) 2009-11-04 2011-05-12 Laboratorios Silanes, S.A. De C.V. Dominios vhnar anti -citocinas
BR112016023980A2 (pt) 2014-04-17 2017-10-17 Teraclon Idf S L anticorpos monoclonais recombinantes vnar que neutralizam o fator de crescimento endotelial vascular (vegf)

Also Published As

Publication number Publication date
US11155612B2 (en) 2021-10-26
WO2018194441A1 (es) 2018-10-25
US20200165331A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
MX2020011133A (es) Composiciones de pienso para animales y usos de las mismas.
MX2018006239A (es) Composiciones que comprenden cepas bacterianas.
MX2018006399A (es) Composiciones que comprenden cepas bacterianas.
MX2020005772A (es) Composiciones que comprenden cepas bacterianas.
MX2017016560A (es) Composiciones que comprenden cepas bacterianas.
TN2017000085A1 (en) Polypeptide having a polyester degrading activity and uses thereof
BR112018009706A8 (pt) composições compreendendo cepas bacterianas
EA201890051A1 (ru) Композиции, содержащие бактериальные штаммы
MX385716B (es) Métodos para mejorar el rendimiento del animal.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX380772B (es) 3-epimerasa.
MX2024004419A (es) Variantes de alfa-glucosidasa acida y usos de las mismas.
MX2020006423A (es) Composiciones de pienso animal y usos de las mismas.
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
EA201691787A1 (ru) Антагонистические антитела, направленные против пептида, кодируемого геном кальцитонина, и способы их применения
MX2016011072A (es) Derivado de pirazol amida.
GB2550510A (en) Beverage with collagen and additional additives
EP4621050A3 (en) Polypeptides having serine protease activity and polynucleotides encoding same and their application in animal feed
EA201300876A1 (ru) Мутантная целлобиогидролаза
MX2020003483A (es) Composiciones de pienso para animales mejoradas y metodos de uso.
ZA201901168B (en) Novel compounds for treating parasitic disease
BR112018003493A2 (pt) variantes de quimosina com propriedades aperfeiçoadas
NZ746539A (en) Combination,therapeutic uses and prophylactic uses
MX2017012610A (es) Composiciones y metodos para inhibir la expresion del gen lect2.
MX2021003035A (es) Composiciones de alimento animal y usos de las mismas.